安森珂(Apalutamide)的适应症和禁忌症是什么
安森珂(Apalutamide)的适应症和禁忌症是什么,安森珂(Apalutamide)适用于治疗有高危转移风险的非转移性去势抵抗性前列腺癌(NM-CRPC)、转移性去势敏感性前列腺癌(mCSPC)、转移性激素敏感性前列腺癌(mHSPC)和去势敏感性前列腺癌(CSPC)的成年患者。安森珂(Apalutamide)禁忌为:1、对阿帕他胺或其任何成分过敏,应禁止使用;2、怀孕和哺乳期的患者禁用;3、男性正在接受阿帕他胺治疗,应采取适当的避孕措施,以避免对伴侣造成潜在的胎儿危险;4、阿帕他胺可能与其他药物相互作用,因此您的医生需要了解您当前正在使用的任何药物,以确保没有危险的相互作用。Title: An Overview of Indications and Contraindications of Apalutamide (安森珂) in Prostate Cancer
Introduction:
Apalutamide, marketed under the brand name "安森珂" (Apalutamide), is a medication used in the treatment of prostate cancer. It belongs to the class of drugs known as androgen receptor inhibitors and is primarily indicated for certain cases of prostate cancer. This article will provide an overview of the indications and contraindications of Apalutamide.
1. Indications of Apalutamide:
Apalutamide is primarily indicated for the treatment of prostate cancer that is non-metastatic, castration-resistant, and at high risk of metastasis. It is used in combination with androgen deprivation therapy (ADT) to delay the spread of the cancer and prolong the time to metastasis. This medication is suitable for patients who have not yet developed detectable metastatic lesions on imaging tests but have rapidly rising prostate-specific antigen (PSA) levels, indicating a high risk of cancer spread.
2. Contraindications of Apalutamide:
While Apalutamide can be beneficial for many patients with prostate cancer, there are certain situations in which its use is contraindicated. These include:
a. Hypersensitivity: Individuals who have previously exhibited hypersensitivity or allergic reactions to Apalutamide or any of its components should not take this medication.
b. Pregnancy and breastfeeding: Apalutamide may cause fetal harm if used during pregnancy, and it is not recommended for use in pregnant women. It is also not known if Apalutamide is excreted in human milk, and thus, breastfeeding women should avoid taking this medication.
c. Severe hepatic impairment: Apalutamide is predominantly metabolized by the liver, and severe hepatic impairment may affect its clearance. Patients with severe liver dysfunction should consult their healthcare provider before initiating treatment.
d. Concurrent use with strong CYP2C8 inhibitors: Apalutamide is metabolized by various enzymes, including CYP2C8. The coadministration of strong CYP2C8 inhibitors, such as gemfibrozil, may increase the exposure to Apalutamide. Thus, caution should be exercised when using Apalutamide with strong CYP2C8 inhibitors, and dosage adjustments may be necessary.
3. Precautions and Warnings:
Apart from contraindications, there are several precautions and warnings associated with the use of Apalutamide. It is important for patients to inform their healthcare provider about any existing medical conditions, ongoing treatments, or medications they are taking before starting Apalutamide therapy. This includes disclosing any history of seizures, psychiatric disorders, cardiovascular disease, and potential drug interactions.
4. Adverse Effects:
Like any medication, Apalutamide may cause certain adverse effects. Common side effects may include fatigue, hot flushes, decreased appetite, weight loss, hypertension, rash, and musculoskeletal pain. It is essential for patients to discuss any persistent or severe side effects with their physicians.
Conclusion:
Apalutamide (安森珂) is an important medication used in the treatment of non-metastatic, castration-resistant prostate cancer at a high risk of metastasis. It should be used in conjunction with androgen deprivation therapy and under the guidance of healthcare professionals. While generally well-tolerated, it is crucial for patients to be aware of the contraindications, precautions, and potential adverse effects associated with Apalutamide and to consult their physicians for personalized advice and monitoring.
张胜泉 | 问药网药师
回答时间 2024-04-27 17:36:59